Advertisement
Organisation › Details
Vesalius Biocapital II S.A. SICAR
Vesalius Biocapital (Vesalius), the specialist life sciences venture capital investor, has supported companies active in human health through venture capital funds since 2007. Since inception, Vesalius has raised over €260 million in three funds and contributed to the development of over 30 companies. The team consists of seasoned life science professionals with healthcare industry, corporate finance and strategy consulting experience, supporting companies through their growth cycle. The team is based in Europe and explores investment opportunities and valuation potential for the portfolio. Vesalius Biocapital III, launched in April 2017, announced a final close with EUR 120 million in commitments in 2019. The fund targets later-stage European life science companies in drug development, medtech, diagnostics and digital health. *
Start | 2011-01-01 established | |
Group | Vesalius Biocapital (Group) | |
Industry | venture capital | |
Industry 2 | BIOTECH | |
Region | Luxembourg (cl=5) | |
Country | Luxembourg | |
Street | 1B rue Thomas Edison | |
City | 1445 Strassen | |
Tel | +352-26-845682 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 78,000,000 (fund size (2017) 2017-05-18) | |
* Document for »About Section«: Topas Therapeutics GmbH. (10/19/20). "Press Release: Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing". Hamburg. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Vesalius Biocapital (Group)
- [1] Catalym GmbH. (11/10/20). "Press Release: Catalym Raises EUR50 Million to Advance GDF-15 Antibody into Clinical Trials for Checkpoint-inhibitor Refractory Patients". Munich....
- [2] OncoDNA S.A.. (2/14/20). "Press Release: OncoDNA Closes Successful Series B Investment Round". Gosselies....
- [3] Vesalius Biocapital Partners Sàrl. (6/25/19). "Press Release: Vesalius Biocapital III Announces Final Close of EUR 120 Million Fund". Strassen, Luxembourg....
- [4] Vesalius Biocapital Partners Sàrl. (5/18/17). "Press Release: Vesalius Biocapital Announces First Close of Its Third Fund". Bertrange....
- [5] Omeicos Therapeutics GmbH. (3/1/17). "Press Release: Omeicos Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top